BeiGene announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has issued an opinion recommending approval for tislelizumab as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma after prior platinum-based chemotherapy.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BGNE:
- BeiGene to hold an investor research and development day
- PepsiCo downgraded, Chewy upgraded: Wall Street’s top analyst calls
- Immix Biopharma second interim clinical trial data readout for IMX-110
- BeiGene initiated with a Buy at Citi
- BeiGene announces FDA acceptance of sNDA for fifth Brukinsa indication